Ares Financial Consulting’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$56.5K Buy
1,490
+220
+17% +$10.1K 0.04% 214
2026
Q2
$60.9K Hold
1,270
– – 0.04% 200
2026
Q1
$46.3K Buy
+1,270
New +$60.2K 0.04% 228

Other funds holding NVO

Ares Financial Consulting's NVO Position: Q3 2026 in Review

Ares Financial Consulting increased its Novo Nordisk (NVO) stake by 17% in Q3 2026, buying an estimated $10.1K and bringing the position to 1,490 shares worth $56.5K. The position accounts for 0.04% of the portfolio, ranked #214.

Ares Financial Consulting first reported a position in NVO in Q1 2026 and has held it in 3 quarters since. The position peaked at $60.9K in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Ares Financial Consulting held 1,490 shares of Novo Nordisk worth $56.5K as of Q3 2026.
  • Ares Financial Consulting bought 220 Novo Nordisk shares in Q3 2026, an estimated $10.1K.
  • Novo Nordisk made up 0.04% of Ares Financial Consulting's portfolio in Q3 2026, its #214 holding.
  • Ares Financial Consulting first reported a position in Novo Nordisk in Q1 2026 and has held it in 3 quarters since.
  • Ares Financial Consulting's Novo Nordisk position peaked at $60.9K in Q2 2026.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.